RLMD — Relmada Therapeutics Share News
0.000.00%
Last trade - 00:00- $350.94m
- $133.21m
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million
Brief: Relmada Therapeutics Inc Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Relmada Therapeutics Q1 net loss widens, cash rises
Brief: Relmada Therapeutics Q1 EPS USD -0.22
Relmada Therapeutics Q4 net loss narrows as expenses decline
Brief: Relmada Therapeutics Q4 EPS USD -0.27
U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems
U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge
Relmada Therapeutics surges premarket as bladder cancer drug shows promising mid‑stage data
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Relmada Therapeutics Q3 net loss narrows
Brief: Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer
Brief: Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01
Brief: Relmada Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Relmada Therapeutics - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing